27.9 C
New York
Sunday, June 14, 2026

Tag: activities

Peak Power Strengthens Board as Demand for Battery Storage and Grid Flexibility Accelerates

Peak Power appoints Doran Hole and Benjamin Baker to its Board of Directors to accelerate battery storage and grid flexibility growth across North America.

BARRANCO GOLD MINING CORP. ENGAGES RIO MINERALS LTD. TO SUPPORT 2026 EXPLORATION PLANNING AT THE KING PROPERTY

CSE: BARFWB:314OTCQB: BRGMFVANCOUVER, BC, June 9, 2026 /PRNewswire/ - Barranco Gold Mining Corp. ("Barranco" or the "Company") is pleased to announce that it has engaged Rio...

Eagle Scout Pathway Produces Young Adults with Measurably Higher Well-Being, Purpose, Leadership and Civic Engagement — Exactly What Families Need Today

New Harris Poll research of more than 3,000 U.S. adults finds Eagle Scouts report 2x lower loneliness, significantly higher purpose and leadership and stronger...

BARRANCO GOLD MINING CORP. ENGAGES RIO MINERALS LTD. TO SUPPORT 2026 EXPLORATION PLANNING AT THE KING PROPERTY

CSE: BARFWB:314OTCQB: BRGMFVANCOUVER, BC, June 9, 2026 /CNW/ - Barranco Gold Mining Corp. ("Barranco" or the "Company") is pleased to announce that it has engaged Rio...

Fusion Fuel Shareholders Approve All Proposed Resolutions, Including Potentially Transformational Royal Uranium Acquisition

Royal Uranium Approval Expected to Advance Company's Potential Transformation into a Diversified Energy Platform

Vivakor Reports First Quarter 2026 Financial Results

Dallas, TX, June 09, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse, and remediation services, today announced financial and operational results for the three months ended March 31, 2026.

Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye

Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tearsCHICAGO, June 9,...

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

CECO Environmental Provides Post-Closing Update on Thermon Transaction

Updates Full Year 2026 Outlook to Incorporate Combination
 Updates Full Year 2026 Outlook to Incorporate Combination

American Fusion Inc. (OTC: AMFN) Provides Development and Testing Update for 5MW Pre-Production Texatron™ Fusion Engine™

American Fusion Provides Development and Testing Update for 5MW Pre-Production Texatron™ Fusion Engine™

EV Battery Market worth $168.95 billion by 2035| MarketsandMarkets™

DELRAY BEACH, Fla., June 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the EV Battery Market is projected to reach USD 168.95 billion by 2035, from USD...

Trilogy Metals Announces Commencement of 2026 Summer Field Program at the Upper Kobuk Mineral Projects in Alaska

VANCOUVER, BC, June 9, 2026 /CNW/ - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today that field...

Trilogy Metals Announces Commencement of 2026 Summer Field Program at the Upper Kobuk Mineral Projects in Alaska

VANCOUVER, BC, June 9, 2026 /PRNewswire/ - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today that field...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsActivities